8/26/25

Nio climbs as JPMorgan upgrades the stock, boosts price target by 67%

Shares of Chinese EV maker Nio are accelerating Tuesday morning following an upgrade from JPMorgan analyst Nick Lai to “overweight” from “neutral.”

JPMorgan hiked its price target for Nio to $8, up 67% from its earlier target of $4.80. With Tuesday’s update, its second boost this month, JPMorgan has now nearly doubled its price target on Nio in the past two weeks.

Nio’s stock has surged more than 35% in August so far on elevated options and share volumes as its multiple Tesla Model Y competitors have become available, sparking enthusiasm from analysts and traders alike.

More Markets

See all Markets

Luke Kawa

41m

T-Mobile and other wireless carriers tumble on SpaceX’s purchase of spectrum licenses from EchoStar

T-Mobile is the worst-performing S&P 500 constituent in early trading, off 5.2% as of 8:27 a.m. ET.

The reason why? SpaceX purchased a pair of spectrum licenses from EchoStar for roughly $17 billion, and as such, SpaceX might no longer need to rely as heavily on T-Mobile going forward.

In August 2022, T-Mobile and SpaceX announced a partnership in which the carrier would help SpaceX’s Starlink provide mobile connectivity from space. The first such satellites launched in January 2024, and T-Mobile ran an ad during the 2025 Super Bowl touting a beta trial of Starlink-powered satellite texting.

However, other wireless providers like AT&T and Verizon are also down (4.5% and 4.2%, respectively) ahead of the open, so this may also simply be a selloff linked to the wireless providers not being the ones to purchase these valuable spectrum licenses themselves — even though AT&T struck a deal with EchoStar in late August to purchase $23-billion in spectrum assets.

Luke Kawa

Please clap

9/7/25

Traders resurrected the long-dead “confidence fairy,” and it's juicing consumption despite the tariffs

It’s not the stock market versus the economy. It’s that the stock market is the economy.

Luke Kawa

9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

Nia Warfield, Luke Kawa

9/5/25

S&P 500 falls as rate-cut optimism fizzles

The S&P 500 gave up early gains to close down 0.3%, while the Nasdaq 100 eked out a 0.1% advance and the Russell 2000 outperformed, rising 0.5%.

Nia Warfield

9/5/25

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

RFK Jr., HHS to Link Autism to Tylenol Use in Pregnancy and Folate Deficiencies

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.